COVID-19 vaccine potency and breadth improved by nanoparticl

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

Related Keywords

, Image Credit , Industry Focus , Coronavirus Disease Covid 19 , Anoparticle , Vaccine , Agonist , Ntibody , Ntigen , B Cell , Fell , Coronavirus , Pg , Cytosine , Hydrogel , Immune Response , Immunization , N Vitro , Ntracellular , Lymph Nodes , Lymphatic System , Athogen , Protein , Eceptor , Espiratory , Cars , Ars Cov 2 , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Yndrome , T Cell ,